Biomarkers in Blood and Tissue Samples From Patients With Epstein-Barr Virus-Positive Hodgkin Lymphoma
RATIONALE: Studying samples of blood and tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer.
PURPOSE: This research trial studies biomarkers in blood and tissue samples from patients with Epstein-Barr virus positive Hodgkin lymphoma.
|Lymphoma Nonneoplastic Condition||Genetic: DNA analysis Genetic: RNA analysis Genetic: cytogenetic analysis Genetic: in situ hybridization Genetic: mutation analysis Genetic: polymerase chain reaction Genetic: western blotting Other: flow cytometry Other: immunohistochemistry staining method Other: medical chart review|
|Study Design:||Observational Model: Cohort
Time Perspective: Retrospective
|Official Title:||Role of the IL-2 Inducible Tcell Kinase in EBV-HLH and EBV+ Hodgkin's Lymphoma|
- Presence of germline ITK mutations
- Influence of ITK mutations on total expression levels or intracellular localization of the ITK protein
- Correlation between ITK mutations with specific clinical or histopathological features of HL
Biospecimen Retention: Samples With DNA
|Study Start Date:||December 2011|
|Study Completion Date:||May 2016|
|Primary Completion Date:||May 2016 (Final data collection date for primary outcome measure)|
- Evaluate germline DNA from patients with Epstein-Barr virus positive (EBV+) and Hodgkin lymphoma (HL) for inducible T-cell kinase (ITK) mutations.
- Examine the effects of ITK mutations on expression of the ITK protein.
- Determine whether ITK mutations correlate with specific clinical or histopathological features of HL.
OUTLINE: Archived blood and tumor tissue samples are analyzed for germline DNA expression and inducible T-cell kinase (ITK) mutations by PCR, IHC, flow cytometry, and western blotting, and EBV-encoded RNA (EBER) using in situ hybridization. Each patient's data, such as date, sex, age, tumor stage and histology at diagnosis, treatment received, response to treatment, development of recurrent disease, date of last follow-up, and outcomes are also collected.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01490801
|Principal Investigator:||Kim E. Nichols, MD, BA||Children's Hospital of Philadelphia|